S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis
Jochen Buechner,Stephan A. Grupp,Stephan A. Grupp,Shannon L. Maude,Shannon L. Maude,Michael Boyer,Henrique Bittencourt,Theodore W. Laetsch,Peter Bader,Michael R. Verneris,Heather E. Stefanski,G.D. Myers,Muna Qayed,Michael A. Pulsipher,Barbara De Moerloose,Hidefumi Hiramatsu,Krysta Schlis,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Christina Peters,Patricia A. Wood,Tetiana Taran,Karen Thudium Mueller,Yiyun Zhang,Susana Rives +25 more
Journal ArticleDOI
Chimeric antigen receptor T-cell therapy for ALL.
TL;DR: Targeted immunotherapy using chimeric antigen receptor (CAR)-modified T cells has emerged as a potent therapy with an innovative mechanism, contributing to both efficacy and the most notable toxicity, cytokine release syndrome, posing a unique challenge for toxicity management.
Journal ArticleDOI
TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521)
Gregory A. Yanik,Stephan A. Grupp,Michael A. Pulsipher,John E. Levine,Kirk R. Schultz,Donna A. Wall,Bryan Langholz,Christopher C. Dvorak,Keith Alangaden,Rakesh K. Goyal,Eric S. White,Jennifer M. Collura,Micah Skeens,Saada Eid,Elizabeth M. Pierce,Kenneth R. Cooke +15 more
TL;DR: The addition of etanercept to high-dose corticosteroids was associated with high response rates and survival in children with IPS, and Plasma levels of proinflammatory cytokines were significantly increased at onset of therapy, subsequently decreasing in responding patients.
Journal ArticleDOI
A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.
Julie R. Park,Susan G. Kreissman,Wendy B. London,Arlene Naranjo,Susan L. Cohn,Michael D. Hogarty,Sheena C. Tenney,Daphne A. Haas-Kogan,Peter J. Shaw,James Duncan Geiger,John J. Doski,Sandra Wooton Gorges,Geetika Khanna,Stephan D. Voss,John M. Maris,Stephan A. Grupp,Lisa Diller +16 more
TL;DR: A multicenter RCT comparing tandem vs. single consolidation in patients with HR-NB improves event-free survival (EFS) for HR- NB and pilot studies suggest that intensification of myeloablative therapy using tandem ASCT further improves outcome.
Journal ArticleDOI
Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation
Paul G. Richardson,Angela R. Smith,Brandon M. Triplett,Nancy A. Kernan,Stephan A. Grupp,Joseph H. Antin,Leslie Lehmann,Maja Miloslavsky,Robin Hume,Alison L. Hannah,Bijan Nejadnik,Robert J. Soiffer +11 more
TL;DR: The relationship between Day +100 survival and treatment initiation before/after specific days post‐diagnosis showed superior survival when treatment was initiated closer to VOD/SOS diagnosis with a statistically significant trend over time for better outcomes with earlier treatment initiation.